Review
doi: 10.2174/1568009013334250.
The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer
Affiliations
- PMID: 12188891
- DOI: 10.2174/1568009013334250
Item in Clipboard
Review
The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer
Curr Cancer Drug Targets.
2001 May.
Abstract
The tyrosine kinase inhibitor STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of cancer. This review details the steps in the development of this agent and highlights why this drug has been so successful in the treatment of chronic myelogenous leukaemia. Future directions including the mechanisms and management of resistance and new therapeutic strategies are discussed. Finally, the literature supporting the use of STI571 in other malignancies, including solid tumors is briefly reviewed.
Similar articles
-
STI571 (Gleevec) as a paradigm for cancer therapy.Trends Mol Med. 2002;8(4 Suppl):S14-8. doi: 10.1016/s1471-4914(02)02305-5. Trends Mol Med. 2002. PMID: 11927282 Review.
-
Perspectives on the development of a molecularly targeted agent.Cancer Cell. 2002 Feb;1(1):31-6. doi: 10.1016/s1535-6108(02)00025-9. Cancer Cell. 2002. PMID: 12086885 Review.
-
STI571: a paradigm of new agents for cancer therapeutics.J Clin Oncol. 2002 Jan 1;20(1):325-34. doi: 10.1200/JCO.2002.20.1.325. J Clin Oncol. 2002. PMID: 11773186 Review.
-
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.Lancet Oncol. 2000 Dec;1:207-11. doi: 10.1016/s1470-2045(00)00149-2. Lancet Oncol. 2000. PMID: 11905636 Review.
-
STI571 (imatinib mesylate): the tale of a targeted therapy.Anticancer Drugs. 2002 Feb;13(2):111-4. doi: 10.1097/00001813-200202000-00001. Anticancer Drugs. 2002. PMID: 11901302 Review.
Cited by
-
Involvement of crk adapter proteins in regulation of lymphoid cell functions.Immunol Res. 2003;28(2):79-91. doi: 10.1385/IR:28:2:79. Immunol Res. 2003. PMID: 14610286 Review.
-
Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.Hum Pathol. 2007 Nov;38(11):1628-38. doi: 10.1016/j.humpath.2007.03.010. Epub 2007 May 22. Hum Pathol. 2007. PMID: 17521701 Free PMC article.
-
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1992-7. doi: 10.1073/pnas.0408283102. Epub 2005 Jan 27. Proc Natl Acad Sci U S A. 2005. PMID: 15677719 Free PMC article.
-
The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target.BMC Neurosci. 2008 Dec 3;9 Suppl 2(Suppl 2):S12. doi: 10.1186/1471-2202-9-S2-S12. BMC Neurosci. 2008. PMID: 19090985 Free PMC article. Review.
-
Design and synthesis of Pictet-Spengler condensation products that exhibit oncogenic-RAS synthetic lethality and induce non-apoptotic cell death.Bioorg Med Chem Lett. 2012 Sep 1;22(17):5707-13. doi: 10.1016/j.bmcl.2012.06.077. Epub 2012 Jun 30. Bioorg Med Chem Lett. 2012. PMID: 22832321 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
